Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F
Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a p
Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS